Overview

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

Status:
Not yet recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids

Phase:

Phase 3

Details

Lead Sponsor:

Equillium

Collaborator:

Biocon Limited